$IRON
Disc Medicine, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024124650 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.171M
YoY Change 79.98%
% of Gross Profit
Research & Development $24.69M
YoY Change 71.2%
% of Gross Profit
Depreciation & Amortization $11.00K
YoY Change -63.33%
% of Gross Profit
Operating Expenses $32.86M
YoY Change 73.31%
Operating Profit -$32.86M
YoY Change 73.31%
Interest Expense $6.362M
YoY Change 31.45%
% of Operating Profit
Other Income/Expense, Net $6.371M
YoY Change 31.2%
Pretax Income -$26.49M
YoY Change 87.81%
Income Tax $114.0K
% Of Pretax Income
Net Earnings -$26.60M
YoY Change 88.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.89
Diluted Earnings Per Share -$0.89
COMMON SHARES
Basic Shares Outstanding 29.76M 29.73M
Diluted Shares Outstanding 29.94M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $487.4M
YoY Change 31.54%
Cash & Equivalents $192.6M
Short-Term Investments $294.7M
Other Short-Term Assets $5.789M
YoY Change 56.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $493.2M
YoY Change 31.77%
LONG-TERM ASSETS
Property, Plant & Equipment $79.00K
YoY Change -56.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $236.0K
YoY Change 103.45%
Total Long-Term Assets $1.993M
YoY Change -10.79%
TOTAL ASSETS
Total Short-Term Assets $493.2M
Total Long-Term Assets $1.993M
Total Assets $495.1M
YoY Change 31.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.553M
YoY Change -58.18%
Accrued Expenses $5.512M
YoY Change -0.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.47M
YoY Change 76.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.712M
YoY Change -44.77%
Total Long-Term Liabilities $1.712M
YoY Change -44.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.47M
Total Long-Term Liabilities $1.712M
Total Liabilities $27.19M
YoY Change 55.14%
SHAREHOLDERS EQUITY
Retained Earnings -$268.5M
YoY Change 62.63%
Common Stock $3.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $468.0M
YoY Change
Total Liabilities & Shareholders Equity $495.1M
YoY Change 31.51%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$26.60M
YoY Change 88.35%
Depreciation, Depletion And Amortization $11.00K
YoY Change -63.33%
Cash From Operating Activities -$17.36M
YoY Change 132.1%
INVESTING ACTIVITIES
Capital Expenditures -$8.000K
YoY Change -116.0%
Acquisitions
YoY Change
Other Investing Activities -$71.10M
YoY Change
Cash From Investing Activities -$71.09M
YoY Change 142080.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 426.0K
YoY Change -7.39%
NET CHANGE
Cash From Operating Activities -17.36M
Cash From Investing Activities -71.09M
Cash From Financing Activities 426.0K
Net Change In Cash -88.03M
YoY Change 1145.05%
FREE CASH FLOW
Cash From Operating Activities -$17.36M
Capital Expenditures -$8.000K
Free Cash Flow -$17.35M
YoY Change 130.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001816736
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y6M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39438
dei Entity Registrant Name
EntityRegistrantName
Disc Medicine, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1612845
dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal Street, Suite 101
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
674-9274
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
dei Trading Symbol
TradingSymbol
IRON
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29757732
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192638000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360382000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
294725000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5789000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5280000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
493152000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
365662000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1678000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1930000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
236000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
234000
CY2024Q3 us-gaap Assets
Assets
495145000
CY2023Q4 us-gaap Assets
Assets
367996000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3553000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12629000
CY2024Q3 iron Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
16332000
CY2023Q4 iron Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1986000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5512000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6159000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
76000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
665000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
25473000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21439000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1712000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1436000
CY2024Q3 us-gaap Liabilities
Liabilities
27185000
CY2023Q4 us-gaap Liabilities
Liabilities
22875000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29748154
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29748154
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24360233
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24360233
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
735761000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
533764000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
741000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268545000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188645000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
467960000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
345121000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
495145000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
367996000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24685000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14419000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71874000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46699000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8171000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4539000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23296000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14712000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
32856000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
18958000
us-gaap Operating Expenses
OperatingExpenses
95170000
us-gaap Operating Expenses
OperatingExpenses
61411000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32856000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18958000
us-gaap Operating Income Loss
OperatingIncomeLoss
-95170000
us-gaap Operating Income Loss
OperatingIncomeLoss
-61411000
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
6362000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
4843000
us-gaap Interest Income Other
InterestIncomeOther
15454000
us-gaap Interest Income Other
InterestIncomeOther
10120000
CY2024Q3 iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
CY2023Q3 iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1500000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6371000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4856000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15449000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8628000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26485000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14102000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-79721000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52783000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
114000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
179000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
67000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-26599000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14122000
us-gaap Net Income Loss
NetIncomeLoss
-79900000
us-gaap Net Income Loss
NetIncomeLoss
-52850000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26599000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26599000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14122000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14122000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-79900000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-79900000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-52850000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-52850000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29935551
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29935551
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24316817
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24316817
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26809605
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26809605
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21605202
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21605202
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-26599000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14122000
us-gaap Net Income Loss
NetIncomeLoss
-79900000
us-gaap Net Income Loss
NetIncomeLoss
-52850000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-48000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-42000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
849000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
783000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
801000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
741000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25798000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14122000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79159000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52850000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
345121000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
806000
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
4058000
CY2024Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
518000
CY2024Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14790000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
245000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26949000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
338071000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
567000
CY2024Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
4091000
CY2024Q2 iron Common Stock In Registered Direct Offering Net Of Issuance Costs
CommonStockInRegisteredDirectOfferingNetOfIssuanceCosts
5472000
CY2024Q2 iron Stock Issued During Period Value Sale Of Common Stock In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInRegisteredDirectOffering
172512000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2024Q2 iron Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriod
66000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-26352000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
488829000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
401000
CY2024Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
4332000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
196000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-48000
CY2024Q3 iron Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriod
849000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-26599000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
467960000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
176600000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1067000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1024000
CY2023Q1 iron Common Stock In Registered Direct Offering Net Of Issuance Costs
CommonStockInRegisteredDirectOfferingNetOfIssuanceCosts
80000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInRegisteredDirectOffering
34148000
CY2023Q1 iron Pre Funded Warrants In Registered Direct Offering Net Of Issuance Costs
PreFundedWarrantsInRegisteredDirectOfferingNetOfIssuanceCosts
66000
CY2023Q1 iron Stock Issued During Period Value Sale Of Pre Funded Warrants In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfPreFundedWarrantsInRegisteredDirectOffering
28206000
CY2023Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
408000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14591000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22781000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
232855000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
242000
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1309000
CY2023Q2 iron Common Stock In Follow On Public Offering Net Of Issuance Costs
CommonStockInFollowOnPublicOfferingNetOfIssuanceCosts
9272000
CY2023Q2 iron Stock Issued During Period Value Sale Of Common Stock In Follow On Public Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInFollowOnPublicOffering
138508000
CY2023Q2 iron Pre Funded Warrants In Follow On Public Offering Net Of Issuance Costs
PreFundedWarrantsInFollowOnPublicOfferingNetOfIssuanceCosts
627000
CY2023Q2 iron Stock Issued During Period Value Sale Of Pre Funded Warrants In Follow On Public Offering
StockIssuedDuringPeriodValueSaleOfPreFundedWarrantsInFollowOnPublicOffering
9373000
CY2023Q2 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
119000
CY2023Q2 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
4879000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15947000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
371219000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
607000
CY2023Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1270000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14122000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
358974000
us-gaap Net Income Loss
NetIncomeLoss
-79900000
us-gaap Net Income Loss
NetIncomeLoss
-52850000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
147000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
75000
us-gaap Share Based Compensation
ShareBasedCompensation
12481000
us-gaap Share Based Compensation
ShareBasedCompensation
3603000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3092000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1500000
iron Noncash Lease Expense
NoncashLeaseExpense
324000
iron Noncash Lease Expense
NoncashLeaseExpense
180000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
42000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
509000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-341000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9076000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7710000
iron Increase Decrease In Accrued External Research And Development Expenses
IncreaseDecreaseInAccruedExternalResearchAndDevelopmentExpenses
14346000
iron Increase Decrease In Accrued External Research And Development Expenses
IncreaseDecreaseInAccruedExternalResearchAndDevelopmentExpenses
132000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-647000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-849000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-385000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-88000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66353000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55666000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
313850000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
23000000
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-290906000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86000
iron Proceeds From Sale Of Common Stock In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfCommonStockInOfferingsNetOfIssuanceCostsPaid
172512000
iron Proceeds From Sale Of Common Stock In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfCommonStockInOfferingsNetOfIssuanceCostsPaid
192126000
iron Proceeds From Sale Of Pre Funded Warrants In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfPreFundedWarrantsInOfferingsNetOfIssuanceCostsPaid
0
iron Proceeds From Sale Of Pre Funded Warrants In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfPreFundedWarrantsInOfferingsNetOfIssuanceCostsPaid
37579000
iron Proceeds From Sale Of Common Stock In At The Market Offerings
ProceedsFromSaleOfCommonStockInAtTheMarketOfferings
14790000
iron Proceeds From Sale Of Common Stock In At The Market Offerings
ProceedsFromSaleOfCommonStockInAtTheMarketOfferings
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1774000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1916000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
441000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
189517000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
231621000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-167742000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
175869000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360616000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194788000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192874000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
370657000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
37000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
78000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1106000
iron Net Increase Decrease In Right Of Use Assets Related To Lease Modifications And Reassessments
NetIncreaseDecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndReassessments
72000
iron Net Increase Decrease In Right Of Use Assets Related To Lease Modifications And Reassessments
NetIncreaseDecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndReassessments
-422000
iron Net Increase Decrease In Lease Liabilities Related To Lease Modifications And Reassessments
NetIncreaseDecreaseInLeaseLiabilitiesRelatedToLeaseModificationsAndReassessments
72000
iron Net Increase Decrease In Lease Liabilities Related To Lease Modifications And Reassessments
NetIncreaseDecreaseInLeaseLiabilitiesRelatedToLeaseModificationsAndReassessments
-392000
iron Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInAccountsPayableAndAccruedExpenses1
0
iron Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInAccountsPayableAndAccruedExpenses1
215000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
487400000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to accrued research and development expenses; stock-based compensation expense; the fair value determinations for instruments accounted for at fair value; the fair value of the contingent value right (“CVR”) (see Note 3); the incremental borrowing rate for determining lease liabilities and right-of-use assets; and income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period in which they become known. Actual results may differ materially from those estimates or assumptions.</span>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and of Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality accredited financial institutions. The Company has concluded that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain</span>
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
293942000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
785000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
294725000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2024Q3 iron Aggregate Fair Value Of Marketable Securities In Unrealized Loss Position
AggregateFairValueOfMarketableSecuritiesInUnrealizedLossPosition
7000000
CY2023Q4 iron Aggregate Fair Value Of Marketable Securities In Unrealized Loss Position
AggregateFairValueOfMarketableSecuritiesInUnrealizedLossPosition
0
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
1
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0
CY2024Q3 us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
CY2023Q3 us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192638000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360382000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
236000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
234000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192874000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360616000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
392000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
245000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4567000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5790000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
708000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
317000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
237000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5512000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6159000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 iron Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
2972432
CY2024Q3 iron Stock Reserved During Period Shares Exercise Of Prefunded Warrants
StockReservedDuringPeriodSharesExerciseOfPrefundedWarrants
204081
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4332000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1270000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12481000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3603000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
51873000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2459037
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M21D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
109078000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
796140
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
59.76
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
198390
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
71691
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
44.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
12664
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
110.57
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2972432
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M7D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
80424000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1571812
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y11M4D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
57338000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4500000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
7900000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0399
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0387
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M20D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y1M20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 iron Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
59.76
CY2023Q3 iron Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
41.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
35.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.68
CY2024Q3 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q3 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
200000
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100000
CY2023Q3 iron Exercise Of Pre Funded Warrants Shares
ExerciseOfPreFundedWarrantsShares
1229224
iron Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1229221
CY2024Q3 iron Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
204081
CY2024Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
7566
CY2024Q3 iron Operating Lease Liability Increase
OperatingLeaseLiabilityIncrease
100000
CY2024Q3 iron Operating Lease Right Of Use Asset Increase
OperatingLeaseRightOfUseAssetIncrease
100000
CY2023Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
9281
us-gaap Lessee Operating Lease Variable Lease Payment Terms And Conditions
LesseeOperatingLeaseVariableLeasePaymentTermsAndConditions
Variable lease payments include the Company’s allocated share of costs incurred for real estate taxes, utilities, and other operating expenses applicable to the leased premises.
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000
CY2024Q3 iron Short Term Bank Loans And Notespayable Percentage
ShortTermBankLoansAndNotespayablePercentage
0.045
CY2024Q3 iron Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 iron Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-124650-index-headers.html Edgar Link pending
0000950170-24-124650-index.html Edgar Link pending
0000950170-24-124650.txt Edgar Link pending
0000950170-24-124650-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img139618140_0.jpg Edgar Link pending
iron-20240930.htm Edgar Link pending
iron-20240930.xsd Edgar Link pending
iron-ex10_1.htm Edgar Link pending
iron-ex31_1.htm Edgar Link pending
iron-ex31_2.htm Edgar Link pending
iron-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
iron-20240930_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending